Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

Overview of attention for article published in Journal of Clinical Oncology, March 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

news: 3 news outlets

twitter: 12 X users

Readers on

mendeley: 56 Mendeley

So far, Altmetric has seen 3 news stories from 3 outlets.

Olaparib Does Not Improve OS vs Chemo in Recurrent Platinum-Sensitive Ovarian Cancer

AJMC, 17 Nov 2023

The use of olaparib as a monotherapy or in combination with cediranib did not provide a statistically significance overall…

Olaparib With/Without Cediranib Does Not Improve OS Vs Chemo in Recurrent Platinum-Sensitive Ovarian Cancer

OncLive, 16 Nov 2023

The use of olaparib as a monotherapy or in combination with cediranib did not provide a statistically significance overall…

Olaparib Alone, in Combination Does Not Improve PFS in Platinum-Sensitive Ovarian Cancer

Cancer Therapy Advisor, 06 Apr 2022

Olaparib alone or in combination with cediranib failed to improve progression-free survival (PFS), compared with platinum…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.